Antibodies to ion channels in paraneoplastic disorders

Brain Pathology

Volumn 9, Issue 2, 1999, Pages 285-291

  Vincent, Angela ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN ANTIBODY; CALCIUM CHANNEL; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; ION CHANNEL; POTASSIUM CHANNEL; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL ANTIBODY; VOLTAGE GATED POTASSIUM CHANNEL ANTIBODY;

ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; AUTOIMMUNITY; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE ASSOCIATION; EATON LAMBERT SYNDROME; LUNG SMALL CELL CANCER; MOUSE; MYASTHENIA GRAVIS; MYOKYMIA; NEUROPATHOLOGY; NONHUMAN; PARANEOPLASTIC SYNDROME; THYMOMA;

EID: 0032920811     PISSN: 10156305     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1750-3639.1999.tb00227.x     Document Type: Conference Paper

References (48)

1. Aarli JA, Lefvert AK, Tender O. Thymoma-specific antibodies in sera from patients with myasthenia gravis demonstrated by indirect haemagglutination. J Neuroimmunol 1981: 1:421-427
2. Arimura K, Nagado TT, Sonoda N, Kurono A, Kameyama M, Watanabe O. Patch clamp studies on cells incubated in AMN sera. Muscle Nerve Supp 7 1998, S59.
3. Bain PG, Motomura M, Newsom-Davis J, Misbah SA, Chapel HM et al Effects of intravenous immunoglobulin on muscle weakness and calcium channel autoantibodies in the Lambert Eaton myasthenic syndrome. Neurology 1996; 47:678-683.
4. Chalk CH, Murray NM, Newsom-Davis J, O'Neill JH, Spiro SG. Response of the Lambert Eaton myasthenic syndrome to treatment of associated small cell lung carcinoma. Neurol 40 1552-1556.
5. Clouston PD, Saper CB, Arbizu T et al. Paraneoplastic cerebellar degeneration. III. Cerebellar degeneration, cncer and the Lambert Eaton myasthenic syndrome. Neurol 1992; 42: 1944-1950.
6. Compston DAS, Vincent A, Newsom-Davis J, Batchelor JR. 1980. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain, 103, 579-601.
7. Drachman DB. Myasthenia gravis. 1994. New England J Med 330:1797-1810.
8. Engel AG, Lambert EH, Howard FM. 1977. Immune complexes (IgG and C3) at the motor endplate in myasthenia gravis. Ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc 52:267-280.
9. Engel AG, Arahata K. 1987. The membrane attack complex of complement at the endplate in myasthenia gravis. Ann NY Acad Sci 505:326-332
10. Engel AG, Nagel A, Fukuoka T, Fukunaga H, Osame M, Lang B, Newsom-Davis J, Vincent A, Wray DW, Peers C. 1989. Motor nerve terminal calcium channels in Lambert-Eaton myasthenic syndrome. Morphologic evidence for depletion and that the depletion is mediated by autoantibodies. Ann N Y Acad Sci 560:278-290.
11. Fukunaga H, Engel AG, Osame M, Lambert EH. 1982. Paucity and disorganisation of presynaptic membrane active zones in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 5:686-697.
12. Hara Y, Ueno S, Uemichi T et al. Neoplastic epithelial cells express a-subunit of muscle nicotinic acetylcholine receptor in thymomas from patients with myasthenia gravis. FEBS Lett 1991: 279: 137-140.
13. Hart IK, Waters C, Vincent A, Newland C, Beeson D, Pongs O, Morris C, Newsom-Davis J. Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. 1997. Ann Neurol 41:238-246.
14. Heidenreich F, Vincent A. Antibodies to ion-channel proteins in thymoma with myasthenia, neuromyotonia, and peripheral neuropathy. Neurology 1998: 50; 1483-1485.
15. Hohlfeld R, Wekerle H. 1994. The role of the thymus in myasthenia gravis. Adv Neuroimmunol 4(4): 373-86.
16. Lang B, Newsom-Davis J, Wray D, Vincent A, Murray NMF. 1981. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet ii:224-226.
17. Lang B, Newsom-Davis J, Prior C, Wray D. 1983. Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to mouse. J Physiol Lond 344:335-345.
18. Lennon VA, Kryzer TH, Griesmann GE, O'Sulleabhain PE, Windebank AJ, Woppmann A, Miljanich GP, Lambert EH. Calcium channel antibodies in the Lambert Eaton syndrome and other paraneoplastic syndromes. New Eng J Med 1995; 332: 1467-1474.
19. Leys K, Lang B, Johnston I, Newsom-Davis J. Calcium channel autoantibodies in the Lambert Eaton myasthenia syndrome. Ann Neurol 1991: 29:307-314.
20. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. 1976. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates and diagnostic value. Neurology 26:1054-1059.
21. Liyanage Y, Teo M, MacLennan C, Buckel A, Beeson D, Willcox N, Newsom-Davis J, Vincent A. Expression of muscle proteins in thymomas of patients with myasthenia gravis. Ann New York Acad Sci 1998; 841: 411-413.
22. MacLennan CA, Beeson D, Willcox N, Vincent A, Newsom-Davis J. Muscle nicotinic acetylcholine receptor RNA expression in hyperplastic and neoplastic myasthenia gravis thymus. Ann NY Acad Sci 1998: 841, 407-410.
23. Maddison P, Newsome-Davis J, Mills KR, Souhami RL, Favourable prognosis in Lambert Eaton myasthenic syndrome and the small cell lung carcinoma. Lancet 353: 117-118, 199
24. Marx, A., A. Wilisch, A. Schultz, A. Greiner, B. Magi, V. Pallini, B. Schalke, K. Toyka, W. Nix, T. Kirchner, and H-K. Müller-Hermelink. Expression of neurofilaments and of a titin epitope in thymic epithelial tumours. Am. J Pathol. 1996; 148:1839-1850.
25. Mason WP, Graus F, Lang B et al Small cell lung cancer: paraneoplastic cerebellar degeneration and the Lambert Eaton myasthenic syndrome. Brain 1997; 120: 1279-1300.
26. Meager, A, Willcox N, Vincent A, Newsom-Davis J. Spontaneous neutralising antibodies to interferon-a and interleukin-12 in thymoma-associated autoimmune disease. Lancet 1997; 350:1596-1597.
27. Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis J. 1995. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 58:85-87.
28. Mygland et al. Thymomas express epitopes shared by the ryanodine receptor. J Neuroimmunol 1995; 62, 79-83.
29. Nagvekar N. Jacobson LW, Willcox N, Vincent A. Expitopes expressed in myasthenia gravis thymomas are not recognized by patients' T cells or autoantibodies. Clin Exp Immunol 1998a: 112:17-20..
30. Nagvekar N, Moody AM, Moss P, Roxanis I, Curnow J, Beeson D, Pantic N, Newsom-Davis J, Vincent A, Willcox N. A pathogenetic role for the thymoma in myasthenia gravis. Autosensitzation of IL-4-producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes. J Clin Invest 1998b; 101; 2268-2277.
31. Newsom-Davis J, Mills KR. 1993. Immunological associations of acquired neuromyotonia (Isaacs' syndrome). Report of five cases and literature review. Brain 453-469.
32. O'Neill JH, Murray NM, Newsom-Davis J. 1988. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 111:577-596.
33. Patrick J, Lindstrom J. 1973. Autoimmune response to acetylcholine receptor. Science 180:871-872.
34. Pinto A, Gillard S, Moss F, et al. Human autoantibodies specific for the a1A calcium channel subunit reduce both P-type and Q-type calcium currents in cerebellar neurons. Proc Natl Acad Sci USA 95: 8328-8333.
35. Riemersma, S., Vincent, A., Beeson, D., Newland, C., Hawke, S., Vernet-der Garabedian, B., Eymard, B. and Newsom-Davis J. 1996 Association of arthrogryposis multiplex congenita with maternal antibodied inhibiting fetal acetylcholine receptor Function. J. Clin. Invest. 98: 2358-2363.
36. Roberts A, Perera S, Lang B, Vincent A, Newsom-Davis J. 1985. Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line. Nature 317:737-739.
37. Sciamanna MA, Griesmann GE, Williams CL, Lennon VA. Nicotinic acetylcholine receptors of muscle and neuronal (a7) types coexpressed in a small cell lung carcinoma. J Neurochem 1997: 69:2302-2311.
38. Shillito P, Molenaar PC, Vincent A, et al 1995. Acquired neuromyotonia: evidence for autoantibodies against K+ channels of peripheral nerves. Ann Neurol. 38:714-722.
39. Sinha S, Newsom-Davis J, Mills K, Byrne N, Lang B, Vincent A. 1991. Autoimmune aetiology for acquired neuromyotonia (Isaacs' syndrome). Lancet 338:75-77.
40. Souadjian JV, Enriques P, Silverstein MN, Pepin, J-M. The spectrum of diseases associated with thymoma. Arch Intern Med 1974; 134; 374-379.
41. Toyka KV, Drachman DB, Griffin DE, Pestronk A, Winkelstein JA, Fischbeck KH, Kao I. 1977. Myasthenia gravis: study of humoral immune mechanisms by passive transfer to mice. N Engl J Med 296:125-131.
42. Vernino S, Admaski J, Kryzer TJ, Fealey RD, Lennon VA. Neuronal nicotinic ACh receptor antibody in acute autonomic neuropathy and cancer-related syndromes. Neurology 1998; 50:1806-1813.
43. Verschuuren JJ, Dalmau J, Tunkel R, Lang B, Graus F, Schramm L, Posner JB, Newsom-Davis J, Rosenfeld MR. Antibodies against the calcium channel b-subunit in Lambert Eaton myasthenic syndrome. Neurol 1998; 50: 475-479.
44. Vincent A, Willcox N, Hill M, Curnow J, MacLennan C, Beeson D. 1988b Determinant spreading and immune responses to acetylcholine receptors in myasthenia gravis. Immunological Rev, in press.
45. Vincent A, Willcox N, Roxanis I, Newsom-Davis J, MacLennan, Beeson D. Thymoma and autoimmune neurological disorders. In: Marx A, Muller-Hemmelink H-K, eds. Epithelial Tumors of the Thymus. New York: Plenum Press, 1997. P 195-204.
46. Vincent A, Whiting PJ, Schluep M et al. Antibody heterogeneity and specificity in myasthenia gravis. Ann NY Acad Sci 1987; 505:326-332.
47. Waterman SA, Lang B, Newsom-Davis J. 1997. Effect of Lambert Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse. Ann Neurol 42: 147-156.
48. Willcox HNA. 1995. Thymic tumours with myasthenia gravis or bone marrow dyscrasias. In Peckham M (ed): Oxford Textbook of Oncology. Oxford University Press, Oxford. P 1562-1568.